Quantitation of sentinel node metastatic burden and Her-2/ neu over-expression accurately predicts residual axillary nodal involvement and extranodal disease in breast cancer

• Published in: European journal of surgical oncology Vol. 39; no. 6; pp. 627 - 633
• Main Authors: Chae, A.W, Vandewalker, K.M, Li, Y.J, Beckett, L.A, Ramsamooj, R, Bold, R.J, Khatri, V.P
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2013
• Subjects: Adult; Aged; Axilla; Axillary lymph node dissection; Breast Neoplasms - chemistry; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Carcinoma, Ductal, Breast - chemistry; Carcinoma, Ductal, Breast - pathology; Carcinoma, Lobular - chemistry; Carcinoma, Lobular - pathology; Confounding Factors (Epidemiology); Female; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Humans; Immunohistochemistry; Linear Models; Lymph Nodes - pathology; Lymph Nodes - surgery; Lymphatic Metastasis - diagnosis; Metastatic breast cancer; Middle Aged; Neoplasm Grading; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2 - analysis; Sentinel Lymph Node Biopsy; Surgery; Up-Regulation; Metastatic breast cancer; Sentinel lymph node biopsy; Axillary lymph node dissection
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2013.02.017

Abstract Background data Recent literature has suggested that completion axillary lymph node dissection (ALND) in breast carcinoma patients with positive SLN may not be necessary. However, a method for determining the risk of non-SLN or extranodal disease remains to be established. Aims To determine if pathological variables from primary tumors and sentinel lymph node (SLN) metastases could predict the probability of non-sentinel lymph node (NSLN) metastases and extranodal disease in patients with breast carcinoma and SLN metastases. Methods 84 women with T1-3 breast cancer and clinically-negative axillae underwent completion ALND. Maximum diameter and width of SLN metastases were measured to calculate metastatic area. When multiple SLNs contained metastases, areas were summed to calculate the Total Metastatic Area (TMA). Multiple linear regression models were used to identify predictive factors. Results Her-2/ neu over-expression increased the odds of NSLN metastases (OR 4.3, p  = 0.01) and extranodal disease (OR 7.9, p  < 0.001). Independent SLN predictors were ≥1 positive SLN (OR, 7.35), maximum diameter and area of SLN metastases (OR 2.26, 1.85 respectively) and TMA (OR, 2.12). Maximum metastatic diameter/SLN diameter (OR 3.71, p  = 0.04) and the area of metastases/SLN area (OR 3.4, p  = 0.04) were predictive. For every 1 mm increase in diameter of SLN metastases, the odds of NSLN extranodal disease increased by 8.5% ( p  = 0.02). TMA >0.40 cm2 was an independent predictor for NSLN metastases and extranodal disease. Conclusion Her-2/ neu over-expression and parameters assessing metastatic burden in the SLN, particularly TMA, predicted the presence of NSLN involvement and extranodal disease in patients with breast carcinoma and SLN metastases.